Our paper on integrated molecular profiling of thymic epithelial tumors (TETs) is now out in @JCOPO_ASCO!
We analyzed 138 TET samples using whole-exome + whole-transcriptome sequencing to map the genomic landscape of thymomas and thymic carcinoma (TC).
https://t.co/NhXpL9Mny8
🚨 GBOT ALERTA – CROWN 7 anos
Lorlatinibe mantém benefício sem precedentes em 1L para CPCNP ALK+ avançado.
📌 PFS mediana ainda não alcançada após ~7 anos
📌 PFS em 7 anos: 55% vs 3% com crizotinibe
📌 Redução de 81% no risco de progressão ou morte (HR 0,19)
🧠 Controle intracraniano sem precedentes:
• Redução de 94% no risco de progressão cerebral (HR 0,06)
• Nenhuma nova progressão intracraniana após 30 meses
• PFS intracraniana em 7 anos: 92%
• Em pacientes sem metástases cerebrais ao diagnóstico, 96% permaneceram livres de novas lesões em 7 anos
✅ Sem alterações nos dados de segurança
✅ Redução de dose não compromete eficácia
🎯 Mais da metade dos pacientes permanece viva e sem progressão após 7 anos — a mais longa PFS já relatada para uma terapia-alvo isolada em tumores sólidos metastáticos.
#NSCLC #ALK #Lorlatinib #CROWN #OncologiaTorácica
@IASLC@SBOC_Oncologia@ASCOPost
📣We had two abstracts selected to be presented at ASCO 2026! A survey about liquid biopsy use in LATAM (Abst 9029) and an analysis of the impact of post-progression access to active therapies on OS in RCT (Abst 1500 - oral session).
👏Congratulations to Dr. Leonardo Santana e Dr. João Apolinário.
🤩Happy and proud!
A shout out also to abstratcs in collaboration with Dr. Elizabeth Santana on hereditary breast cancer, male brrast cancer and use ok CDKi!
@NEJM dropping the full embargoed LBA at 6am before the #ASCO26 presentation is like texting someone the movie ending while they're still parking the car. At least let us pretend we don't know. 🍿
Seven-year follow-up of CROWN confirms the durability of first-line #lorlatinib in ALK+ NSCLC: 55% remain progression-free at 7 years, median PFS unreached, and intracranial control is unprecedented (HR for IC progression 0.06). A new benchmark in targeted therapy. #ASCO26
Sun-vozertinib rose over the frontline horizon today showing improved PFS over doublet chenotherapy for pts w advanced EGFR exon 20insertion mutation positive pts and w an oral option could be a fair 1st line option along w PAPILLON
But noting a somewhat mediocre PFS of slightly >10m, notable adverse event profile (40%+ dose reductions) and unclear CNS activity, the therapeutic window for exon20 ins+ pts remains narrow- the window for better drugs remains wide
#ASCO26
#lcsm
Sunvozertinib (WU-KONG28 trial): a new major player on front line to replace chemoT - Amivantamab: very likely and while awaiting the next ones, including firmonertinib for EGFR Ex20ins pts. World of EGFR definitely never stops its scientific revolution and progress…@NEJM#EGFR
ICYMI, @ASCO abstracts release next week! Here's my top 10 lists for:
👉 Lung Cancer Abstracts to watch #lcsm
👉 Devp. therapeutics Abstracts to watch
👉 #AI in oncology Abstracts to watch
and ofcourse, the #plenaries
2 weeks to go for #ASCO26! @OncoAlert@oncodaily
🚨 GBOT ALERTA – Estadiamento mediastinal no CPCNP
Diretriz do Grupo Brasileiro de Oncologia Torácica (GBOT):
📌 TC e PET-CT têm acurácia limitada para N2/N3
• sROC: 0,73 e 0,87
⚠️ PET-CT pode gerar falso-positivos em áreas endêmicas para granulomatoses (ex: TB)
✅ EBUS + EUS = maior acurácia diagnóstica
• sROC: 0,99
• Performance comparável à mediastinoscopia
🧠 Pontos-chave:
• Imagem isolada NÃO basta
• Confirmação tecidual é essencial
• EBUS/EUS deve ser primeira linha
• Mediastinoscopia fica reservada para casos selecionados
🎯 Estadiamento preciso evita cirurgias desnecessárias e acelera o tratamento.
#NSCLC #EBUS #EUS #PETCT #OncologiaTorácica
#GBOTjovem
@SBOC_Oncologia@IASLC
https://t.co/MgMAdfokkA
May is Thymic Malignancy Awareness Month!
Join us for a FREE webinar series covering the latest in thymic epithelial tumors.
Register: https://t.co/tGQue7ojq7
📋 May 20 — Clinical Guidelines Updates
🏥 May 20 — Multidisciplinary Care: Surgery to QoL
🧬 May 22 — Clinical Trials & Emerging Therapies
🔬 May 28 — Challenges in Thymic Tumor Pathology
🌍 Jun 9 — Treatment Access Worldwide
@Itmig_society